DiaMedica Therapeutics Inc. (DMAC) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results
August 14, 2023 4:13 PM EDTConference Call and Webcast August 15 at 8:00 am Eastern Time / 7:00 am Central Time
Company Resumes ReMEDy2 Clinical Trial after Clinical Hold Lifted Company Completed a $37.5M At-The-Market Private Placement, Cash Runway Into 2026 Company Completed an Additional Safety Cohort of ACEi Patients in its Phase 1C Healthy Volunteer StudyMINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update... More
